Using Phenazopyridine for In-office Cystoscopy

Launched by BOSTON UROGYNECOLOGY ASSOCIATES · Mar 21, 2016

Keywords

ClinConnect Summary

All potentially eligible participants will have had a complete history, physical examination, urinalysis and urine culture for clinical purposes. After eligibility is confirmed and written, informed consent is obtained, participants will be randomized to one of the two study arms. Participants randomized to phenazopyridine arm will receive 200 mg by mouth approximately 60 minutes prior to the scheduled cystoscopy. During the cystoscopy, at various time points, the time will be recorded.The color of the efflux will also be documented.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female patients undergoing in-office diagnostic cystoscopy at Boston Urogynecology Associates
• Exclusion Criteria:
• • Women who have taken vitamin B the day of the cystoscopy
• • Cystoscopy with concurrent treatments such as botulinum toxin or periurethral bulking injections
• • Allergy to phenazopyridine

Trial Officials